Advances in dementia with Lewy bodies

Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity under the broader term Lewy body dementia , which also includes Parkinson’s disease dementia. Recent advances in DLB include publica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Melissa J. Armstrong
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7ffa8b25e19a417d9d2afa3c5485d993
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ffa8b25e19a417d9d2afa3c5485d993
record_format	dspace
spelling	oai:doaj.org-article:7ffa8b25e19a417d9d2afa3c5485d9932021-11-23T23:04:15ZAdvances in dementia with Lewy bodies1756-286410.1177/17562864211057666https://doaj.org/article/7ffa8b25e19a417d9d2afa3c5485d9932021-11-01T00:00:00Zhttps://doi.org/10.1177/17562864211057666https://doaj.org/toc/1756-2864Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity under the broader term Lewy body dementia , which also includes Parkinson’s disease dementia. Recent advances in DLB include publication of updated diagnostic criteria and recognition of prodromal DLB states, including mild cognitive impairment, delirium-onset, and psychiatric-onset forms. Research criteria for the mild cognitive impairment form of DLB were published in 2020. Increasing research shows that concomitant Alzheimer’s disease pathology in individuals with DLB is common in addition to the α-synucleinopathy pathology. This has implications for biomarker use and expected progression. Identifying biomarkers for DLB is an area of active research. Cerebrospinal fluid and skin biopsy tests are now commercially available in the United States, but their role in routine clinical care is not yet established. Additional research and biomarkers are needed. Research suggests that median survival after DLB diagnosis is 3–4 years, but there are rapidly and slowly progressive forms. Most individuals with DLB die of complications of the disease. Clinical trials for individuals with DLB have increased over the last 5 years, targeting both symptoms and underlying pathology. Effective therapies remain an unmet need, however. This review focuses on recent advances with an emphasis on literature that informs clinical care.Melissa J. ArmstrongSAGE PublishingarticleNeurology. Diseases of the nervous systemRC346-429ENTherapeutic Advances in Neurological Disorders, Vol 14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Melissa J. Armstrong Advances in dementia with Lewy bodies
description	Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity under the broader term Lewy body dementia , which also includes Parkinson’s disease dementia. Recent advances in DLB include publication of updated diagnostic criteria and recognition of prodromal DLB states, including mild cognitive impairment, delirium-onset, and psychiatric-onset forms. Research criteria for the mild cognitive impairment form of DLB were published in 2020. Increasing research shows that concomitant Alzheimer’s disease pathology in individuals with DLB is common in addition to the α-synucleinopathy pathology. This has implications for biomarker use and expected progression. Identifying biomarkers for DLB is an area of active research. Cerebrospinal fluid and skin biopsy tests are now commercially available in the United States, but their role in routine clinical care is not yet established. Additional research and biomarkers are needed. Research suggests that median survival after DLB diagnosis is 3–4 years, but there are rapidly and slowly progressive forms. Most individuals with DLB die of complications of the disease. Clinical trials for individuals with DLB have increased over the last 5 years, targeting both symptoms and underlying pathology. Effective therapies remain an unmet need, however. This review focuses on recent advances with an emphasis on literature that informs clinical care.
format	article
author	Melissa J. Armstrong
author_facet	Melissa J. Armstrong
author_sort	Melissa J. Armstrong
title	Advances in dementia with Lewy bodies
title_short	Advances in dementia with Lewy bodies
title_full	Advances in dementia with Lewy bodies
title_fullStr	Advances in dementia with Lewy bodies
title_full_unstemmed	Advances in dementia with Lewy bodies
title_sort	advances in dementia with lewy bodies
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/7ffa8b25e19a417d9d2afa3c5485d993
work_keys_str_mv	AT melissajarmstrong advancesindementiawithlewybodies
_version_	1718416103530561536

Advances in dementia with Lewy bodies

Ejemplares similares